Navigation Links
Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012
Date:3/1/2012

BOONTON, N.J., March 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company's senior management team will host a conference call and live audio webcast on Thursday, March 8, 2012 at 11 a.m. ET to discuss fourth quarter and full-year 2011 financial results.

Interested participants and investors may access the conference call at 11 a.m. ET by dialing 866-277-1181 (U.S./Canada) or 617-597-5358 (international); participant code 82583482.  An audio webcast can be accessed by logging on to the Investors and Media section under the Events tab of the Unigene web site, http://www.unigene.com.  

A telephonic replay of the call will be available for two weeks beginning at 2 p.m. ET on March 8.  Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 18902945. The webcast replay will remain available in the Investors section of the Unigene Laboratories web site for 30 days.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com


Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
jrando@tiberend.com  / amielach@tiberend.com


'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
2. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
3. Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
4. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
5. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
6. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
7. ARUP Laboratories Announces Creation of Business Innovations Division
8. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
9. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
10. Regeneron Announces March 2012 Investor Conference Presentations
11. MiMedx Group Announces 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Jan. 20, 2017 Interpace Diagnostics Group, ... that provides clinically useful molecular diagnostic tests and ... into a securities purchase agreement with three  institutional ... of common stock in a registered direct offering.  ... agreed to sell to the same investors warrants ...
(Date:1/20/2017)... , January 20, 2017 Stock-Callers.com ... conditions have influenced the most recent performances of select ... (NASDAQ: RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... by Grand View Research, global Biotech market size is expected to ...
(Date:1/19/2017)... Research Future has a half cooked research report on Global Liquid ... and expected to reach USD 450 Million by the end of ... ... assessed as a swiftly growing market and expected that the market ... There has been a tremendous growth in the prevalence of cancer ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, ... biopharmaceutical and medical device manufacturers and regulators, is proud to announce the worldwide ... email client designed to provide product vigilance departments with the flexibility and ease ...
Breaking Biology Technology:
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
Breaking Biology News(10 mins):